Clinical trials: ALS

CYTOKINETICS CY 4026:  A Phase IIb, Multi-National, Double-blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients with Amyotrophic Lateral Sclerosis
  • The purpose of this study is to test the safety and efficacy of the oral investigational agent CK-2017357 and to see if it can help muscle strength and endurance in ALS patients.
Principal Investigator:  Dr. Kimberly Goslin

Sponsor:  Cytokinetics


NeuRX DPS POST-APPROVAL STUDY:  Diaphragm Pacing System for Ventilatory Assist in Amyotrophic Lateral Sclerosis data collection study for Diaphragmatic Pacing System Humanitarian Use Device for patients with ALS.
  • The purpose of this study is to evaluate and collect data on the NeuRx DPS device.  It is hoped that the NeuRx DPS device will help maintain your breathing function in people wiht ALS through conditioning the diaphragm.
Principal Investigator:  Dr. Kimberly Goslin

Sponsor:  Synapse Biomedical, Inc.


Neudexta-NUE-2012:  The Experimental Treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS). 
  • The purpose of this study is to determine if Nuedexta exerts a palliative effect on speech, swallowing and salivation in patients with ALS.
Principal Investigator:  Dr. Kimberly Goslin

Sponsor:  ALS Association (ALSA) and the Northeast ALS Consortium (NEALS)
Contact:  Providence ALS Research Nurse, Kimberly Siebers, at 503 962-1171